Merck KGaA In The Market For Bolt-On M&A

Will Have €5bn-€9bn To Invest By End of 2022

Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."

Merck KGaA Darmstadt
• Source: Archive

Merck KGaA has presented a promising growth story for the next few years to analysts, targeting an increase in group sales to €25bn by 2025 and looking at acquisitions in the high single-digit billion euro range.

The German firm gave a strategy update at its virtual capital markets day on 9 September where CEO Belén Garijo...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.